This inventor holds 1 USPTO granted patent. Top assignee: Sentoclone International Ab. Active years: 2011.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2011
Title: Innovator Spotlight: Magnus Thöm - Pioneering Cancer Treatment with T-Lymphocytes
Introduction: Magnus Thöm, a visionary inventor hailing from Uppsala, Sweden, has revolutionized the field of oncology with his groundbreaking patent on treating colon cancer using tumour-reactive T-lymphocytes.
Latest Patents: Magnus Thöm holds a pivotal patent for a method involving expanded tumour-reactive CD4+ helper and/or CD8+ T-lymphocytes obtained from sentinel or metinel lymph nodes draining colon tumours, offering a novel and effective treatment for colon cancer and metastases.
Career Highlights: Magnus Thöm is a key figure at Sentoclone International Ab, a cutting-edge company at the forefront of immunotherapeutic research and development. His expertise in cancer treatment has brought significant advancements to the medical industry.
Collaborations: Among Magnus Thöm's colleagues is Ola Winqvist, a collaborator who has worked alongside him in the innovative field of immunotherapy for cancer. Together, they continue to push the boundaries of medical science.
Conclusion: Magnus Thöm's dedication to improving cancer care through pioneering immunotherapeutic approaches underscores his invaluable contributions to the medical community. His patent stands as a testament to his commitment to advancing the field of oncology and improving patient outcomes.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile